Here's what Stat said: "The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease."
Here's the way the Post reported what Stat said and how YOU highlighted it: "The early signs come from a small study of just 125 infected patients at a Chicago hospital, part of a broader trial for the Gilead Science drug. Of those patients, 113 had severe complications, STAT News reported."
Gilead has already responded to these complaints....I shouldn't have to: "Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for COVID-19." https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155076681
"Was there a control?" No. "125 patients, 2 died. Isn’t that (~2%) the mortality rate for patients with symptoms?" I'm not sure. Are you?
Do other treatments result in the majority of patients with severe disease being released in less than 10 days?
I don't own Gilead shares (wish I did) but it would be nice if some drug could treat this disease successfully and if some other company, large or small, comes along and reports similar or better results than Gilead's you can be sure that I'll post about it if I notice and I would hope that I'd have a little company and not a litany of complaints.
Per MedicineNet...... Complication: In medicine, an unanticipated problem that arises following, and is a result of, a procedure, treatment, or illness. A complication is so named because it complicates the situation.
The Post could have used "disease" as the original article stated, but they chose to use a term that could have meant that the patients problems could actually have come from the treatment itself. That's very dirty pool and lousy journalism. Highlighting it didn't help.
News 
Market Data 
Discover 
